Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B, Wrba F
Department of Clinical Pathology, University of Vienna, Medical School, Austria.
J Pathol. 2000 Mar;190(4):450-6. doi: 10.1002/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8.
Immunohistochemistry (IHC) is a cheap and rapid method to detect p53 inactivation but the results are often discordant with gene mutation analysis. This study aimed to investigate whether there is a difference in the immunohistochemical staining patterns of p53-positive cells on comparing tumours with inactivating gene mutations with those without. Tissues of 142 colorectal cancers were investigated for p53 inactivation simultaneously by IHC and gene analysis using SSCP of exons 4-9 and sequencing. In addition, tumours were investigated immunohistochemically for the expression of mdm-2 protein, known to be transcriptionally transactivated by the wild-type (wt) p53 gene. p53-positive cells of tumours without detectable p53 gene mutations were microdissected using a PALM laser microscope system and subjected to p53 sequence analysis. Among the 142 cases of colorectal cancer (male/female=88/54; mean age 66a+/-11 years, range 24-90 years), 74% (n=105) of tumours were positive by p53 IHC and mutations in the p53 gene were found in 51% (73 patients). In 16% (12 patients) with mutations in the p53 gene, IHC for p53 was negative. In tumours with mutations in the p53 gene and positive p53 IHC, staining of all nuclei of the tumour was more frequently (57/61, 93%) found than in tumours without p53 gene mutations, where staining of scattered single cells was predominantly seen (29/44, 66%; p<0.0001). mdm-2 positivity (n=33) showed only staining of scattered single cells, predominantly (24/33, 82%; p<0.0001) in tumours without gene mutations. Single cell microdissection followed by mutation analysis of scattered p53-positive cells revealed no gene mutations. A scattered positive immunohistochemical reactivity of p53 in colorectal cancer cells might therefore represent a functionally active non-mutated p53 gene and should not be considered as a marker of gene mutation and inactivation.
免疫组织化学(IHC)是一种检测p53失活的廉价且快速的方法,但结果常常与基因突变分析不一致。本研究旨在探讨在比较具有失活基因突变的肿瘤与无失活基因突变的肿瘤时,p53阳性细胞的免疫组织化学染色模式是否存在差异。通过免疫组织化学和使用外显子4 - 9的单链构象多态性(SSCP)及测序进行基因分析,同时检测了142例结直肠癌组织中的p53失活情况。此外,对肿瘤进行免疫组织化学检测,以分析已知由野生型(wt)p53基因转录激活的mdm - 2蛋白的表达情况。使用PALM激光显微镜系统对未检测到p53基因突变的肿瘤中的p53阳性细胞进行显微切割,并进行p53序列分析。在142例结直肠癌病例中(男/女 = 88/54;平均年龄66±11岁,范围24 - 90岁),74%(n = 105)的肿瘤p53免疫组织化学检测呈阳性,51%(73例患者)发现p53基因突变。在16%(12例患者)p53基因突变的病例中,p53免疫组织化学检测为阴性。在p53基因突变且p53免疫组织化学检测呈阳性的肿瘤中,肿瘤所有细胞核的染色比无p53基因突变的肿瘤更常见(57/61,93%),在无p53基因突变的肿瘤中,主要可见散在单个细胞的染色(29/44,66%;p<0.0001)。mdm - 2阳性(n = 33)仅显示散在单个细胞的染色,主要(24/33,82%;p<0.0001)出现在无基因突变的肿瘤中。对散在的p53阳性细胞进行显微切割后进行突变分析,未发现基因突变。因此,结直肠癌细胞中p53散在的阳性免疫组织化学反应可能代表功能活跃的非突变p53基因,不应被视为基因突变和失活的标志物。